Key result
Latent donor RCMV accelerates chronic rejection despite ganciclovir, likely driven by tertiary lymphoid structures.
Why the study?
Does ganciclovir treatment prevent chronic allograft rejection and transplant vascular sclerosis in RCMV-naïve recipients of latently RCMV-infected donor hearts?
Does ganciclovir treatment prevent chronic allograft rejection and transplant vascular sclerosis in RCMV-naïve recipients of latently RCMV-infected donor hearts?
Latent CMV infection in donor hearts induces tertiary lymphoid structures prior to transplantation, accelerating chronic rejection in naïve recipients in a ganciclovir-insensitive manner.
Ganciclovir does not prevent latent donor RCMV-driven chronic rejection in naïve rat recipients; leaves open whether pre-transplant TLS targeting alters outcomes in cardiac allografts.
Human cytomegalovirus (HCMV) infection is associated with the acceleration of transplant vascular sclerosis (TVS) and chronic allograft rejection (CR). HCMV-negative recipients of latently HCMV infected donor grafts are at highest risk for developing CMV disease. Using a rat heart transplant CR model, we have previously shown that acute rat CMV (RCMV) infection following transplantation significantly accelerates both TVS and CR. Here, we report that RCMV-naïve recipients of heart allografts from latently RCMV-infected donors undergo acceleration of CR with similar kinetics as acutely infected recipients. In contrast to acutely infected recipients, treatment of recipients of latently infected donor hearts with ganciclovir did not prevent CR or TVS. We observed the formation of tertiary lymphoid structures (TLOs) containing macrophages and T cells in latently infected hearts prior to transplantation but not in uninfected rats. Moreover, pathway analysis of gene expression data from allografts from latently infected donors indicated an early and sustained production of TLO-associated genes compared to allografts from uninfected donors. We conclude that RCMV-induced TLO formation and alteration of donor tissue T cell profiles prior to transplantation in part mediate the ganciclovir-insensitive rejection of latently infected donor allografts transplanted into naïve recipients by providing a scaffold for immune activation.
No takes yet. Share an insight, caveat, or question.
Orloff et al. (2010) studied Heart transplant chronic allograft rejection. Latent RCMV infection in donor grafts vs. Uninfected donor grafts was evaluated on Acceleration of chronic allograft rejection and transplant vascular sclerosis. Latent RCMV infection in donor heart allografts accelerated chronic rejection in naïve recipients, which was not prevented by ganciclovir, likely mediated by pre-transplant tertiary lymphoid structures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: